The success of life sciences companies will depend on products and services not yet found in a companies offerings in the next decade. Much of those products will be brought to companies through the merger and acquisitions of small to mid-sized companies. This panel will discuss:
- When is the right time to get acquired?
- What is the survival rate of c-suite after an acquisition?
- Why is an acquisition better than a collaboration?
- What are the key issues in the due diligence process that can hurt the value of the deal?
- How does big pharma prepare for pricing negotiations and how can a smaller seller be prepared
- What types of steps can be taken to prepare a forecast that drives value negotiations
- How can this analysis be leverage in negotiating a collaborative or co-partner agreement
Panelists include: Ben Clark, Partner, Deloitte & Touche LLP; Jay Jesclard, Senior Manager, Deloitte Financial Advisory Services LLP; Linda Justice, Senior Manager, Deloitte Financial Advisory Services LLP; and Ronda Sroka, Partner, Deloitte Tax LLP.
Related Insights
May 30, 2025
Foley Career Perspectives
Foley Mental Health Month Program: Enhancing Performance Through High-Quality Connections
Foley & Lardner endeavors to create a high-performance culture that also prioritizes well-being — a culture where every member of the…
May 29, 2025
Manufacturing Industry Advisor
Foley Automotive Update
Analysis by Julie Dautermann, Competitive Intelligence Analyst Foley is here to help you through all aspects of rethinking your long-term…
May 29, 2025
Foley Viewpoints
Supreme Court Clarifies Scope of Federal Fraud Statutes in Connection with False DBE Reporting on Federally Funded Projects
On May 22, 2025, the U.S. Supreme Court issued a significant decision in Kousisis v. United States, affirming a six-year prison sentence for a contractor convicted of federal wire fraud for misrepresenting use of a disadvantaged business enterprise supplier on a project.